NAFLD (non-alcoholic fatty liver disease) represents a spectrum of fatty liver diseases associated with an increased risk of Type 2 diabetes and cardiovascular disease. The spectrum of fatty liver diseases comprises simple steatosis, steatosis with inflammation [i.e. NASH (non-alcoholic steatohepatitis)], fatty liver disease with inflammation and fibrosis (severe NASH) and cirrhosis. The molecu...

Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are among the most common causes of chronic liver diseases in the westernized world. NAFLD and ALD are frequently accompanied by extrahepatic complications, including hepatocellular carcinoma and cardiovascular diseases, which have a negative impact on patient survival. The chronic ingestion of an excessive daily diet c...

Silymarin, the polyphenolic fraction from Milk Thistle (Silybum marianum) and its main component silybinin, are used almost exclusively for hepatoprotection in humans. Silymarin offers good protection in various toxic models of experimental liver diseases in laboratory animals. It effects, by antioxidative, anti-inflammatory, antifibrotic, antilipid peroxidative, membrane stabilizing and liver ...

As the number of individuals with non-alcoholic fatty liver disease (NAFLD) has increased, the influence of NAFLD on other metabolic diseases has been highlighted. Accumulating epidemiologic evidence indicates that NAFLD not only affects the liver but also increases the risk of extra-hepatic diseases such as type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, hypertension, cardiovascula...

Metabolomics as the new omics technique develops after genomics, transcriptomics, and proteomics and has rapid development at present. Liver diseases are worldwide public health problems. In China, chronic hepatitis B and its secondary diseases are the common liver diseases. They can be diagnosed by the combination of history, virology, liver function, and medical imaging. However, some patient...

Background: Progressive fibrosis and cirrhosis, clinically presenting as end-stage liver disease are common outcomes in alcoholic hepatitis as well as non-alcoholic fatty liver disease(NAFLD). In these processes, a series of changes occurs in liver tissues leading to cell death, remodeling, fibrosis and regeneration. The aim of this study is to identify potential novel biomarkers for non-invasi...

Globally, an estimated one million deaths occur annually due to complications of cirrhosis. Cirrhosis with end stage liver disease [ESLD] is a leading cause death noncommunicable diseases in Sri Lanka. Non-alcoholic fatty [NAFLD] and alcohol related [ARLD] are the principal causes ESLD cirrhosis Liver transplantation remains only curative treatment for such patients. Multiorgan dysfunction hemo...

BACKGROUND Alcoholic liver disease is the leading cause of cirrhosis worldwide. Due to an increase in alcohol overuse, alcoholic liver disease has become an increased burden on health care systems. Abstinence from alcohol remains the cornerstone of alcoholic liver disease treatment; however, this approach is hampered by frequent relapse and lack of specific therapy for treating advanced cases o...

Non-alcoholic fatty liver disease (NAFLD) is a heterogeneous disease that may range from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) which can progress to advanced fibrosis and cirrhosis and is currently one of the most common chronic liver diseases in Korea and worldwide. Furthermore, in parallel with the increasing prevalence of obesity, type 2 d...

conclusions the apri had the highest sensitivity and specificity (64% and 71%, respectively) for prediction of the presence of liver disease. we suggest that apri may be applicable for the detection of a severe liver disease. objectives in this study, we evaluated and compared several available indices of the severity of liver diseases in patients with hepatitis. patients and methods exclusion ...